Pharvaris N.V. Announces 2024 Annual General Meeting

Ticker: PHVS · Form: 6-K · Filed: 2024-06-11T00:00:00.000Z

Sentiment: neutral

Topics: agm, shareholder-meeting, corporate-governance

TL;DR

Pharvaris AGM on July 10th - vote on accounts, pay, and auditor.

AI Summary

Pharvaris N.V. filed a Form 6-K on June 11, 2024, announcing its Annual General Meeting (AGM) of Shareholders. The meeting is scheduled for July 10, 2024, and will be held virtually. Key agenda items include the adoption of the annual accounts, approval of the remuneration report, and the reappointment of the auditor.

Why It Matters

Shareholders will vote on critical company matters, including financial reporting and auditor selection, which can impact investor confidence and future operations.

Risk Assessment

Risk Level: low — This filing is a routine announcement of an upcoming shareholder meeting and does not contain new financial or operational information that would typically increase risk.

Key Players & Entities

FAQ

When and where will the Pharvaris N.V. Annual General Meeting be held?

The Annual General Meeting of Shareholders will be held virtually on July 10, 2024.

What are the main items on the agenda for the AGM?

The agenda includes the adoption of the annual accounts, approval of the remuneration report, and the reappointment of the auditor.

What form is Pharvaris N.V. filing?

Pharvaris N.V. is filing a Form 6-K.

What is the company's fiscal year end?

The company's fiscal year ends on December 31.

What is the principal executive office address for Pharvaris N.V.?

The principal executive office is located at Emmy Noetherweg 2, 2333 BK Leiden, The Netherlands.

From the Filing

0000950170-24-071611.txt : 20240611 0000950170-24-071611.hdr.sgml : 20240611 20240611065206 ACCESSION NUMBER: 0000950170-24-071611 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240611 FILED AS OF DATE: 20240611 DATE AS OF CHANGE: 20240611 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharvaris N.V. CENTRAL INDEX KEY: 0001830487 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40010 FILM NUMBER: 241034590 BUSINESS ADDRESS: STREET 1: J.H. OORTWEG 21 STREET 2: 2333 CH LEIDEN CITY: LEIDEN STATE: P7 ZIP: 00000 BUSINESS PHONE: 31 (0)71 203 6410 MAIL ADDRESS: STREET 1: J.H. OORTWEG 21 STREET 2: 2333 CH LEIDEN CITY: LEIDEN STATE: P7 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: Pharvaris, B.V. DATE OF NAME CHANGE: 20201029 6-K 1 6-k_agm_pr_announcement_.htm 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of June 2024 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2   2333 BK Leiden   The Netherlands (Address of principal executive office)   Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐   Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐   Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.   PHARVARIS N.V.     On June 11, 2024, Pharvaris N.V. (the “Company”) issued a press release announcing its 2024 annual general meeting of shareholders to be held on June 28, 2024 and made available to its shareholders certain other materials in connection with such meeting. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The materials made available to the Company’s shareholders are attached as Exhibits 99.2 and 99.3 hereto and are incorporated by reference herein. Exhibit 99.4 contains the Company’s Annual Report for the year ended December 31, 2023, which is furnished herewith.         SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.   PHARVARIS N.V.     Date: June 11, 2024 By: /s/ Berndt Modig   Name: Berndt Modig   Title: Chief Executive Officer   EXHIBIT INDEX   Exhibit No.   Description       99.1   Press Release dated Jun

View on Read The Filing